LAS17 is a selective and highly effective inhibitor of glutathione S-transferase Pi (GSTP1), which inhibits GSTP1 activity in vitro in a concentration-dependent manner. LAS17 has anti-tumor activity and inhibits breast cancer cell growth.

METHODS: To determine whether LAS17 (0-100 μM) inhibits GSTP1 activity, an in vitro activity assay was performed, monitoring the transfer of glutathione (GSH) to 1-bromo-2,4-dinitrobenzene (BDNB) spectrophotometrically.
RESULTS:LAS17 inhibited GSTP1 activity in vitro in a concentration-dependent manner. [1]
METHODS: 231MFP cells were treated with LAS17 (10 μM, 48 hours) and their serum-free cell viability was measured.
RESULTS:LAS17 treatment reduced the level of phosphorylated S6 downstream of mTOR and S6 kinase in 231MFP breast cancer cells. [2]

METHODS: LAS17 (20 mg/kg, intraperitoneal injection, once a day) was used to treat 231MFP tumor xenografted mice in immunodeficient mice and the tumor growth was observed.
RESULTS:LAS17 significantly inhibited the growth of 231MFP breast tumor xenografts in immunodeficient mice, had no cytotoxicity, and had no effect on the body weight of mice. [2]